 |
 |
     |
|
| Creating the next generation of cancer treatments |
 |
|
 |
 AR-12AR-12 is an orally available, targeted anti-cancer agent that has been shown in pre-clinical studies to inhibit PDK-1, a protein in the PI3K/Akt pathway that is involved in the growth and proliferation of cells, including cancer cells. AR-12 may also cause cell death through the induction of stress in the endoplasmic reticulum. We are currently conducting a multi-centered Phase I clinical study of AR-12 in adult patients with advanced or recurrent solid tumors or lymphoma. CLINICAL PROGRAM For information about the current clinical program, please go to [ LINK HERE ] | | 
Arno Therapeutics, Inc. |
©2011 Arno Therapeutics, Inc. | Privacy Policy |